EDN1 and glomerulosclerosis: Most of the evidence about these effects of ET-1 has been provided by numerous studies demonstrating beneficial effects of ET-1 receptor inhibition or ETRKO in models of kidney diseases that lead to glomerulosclerosis and/or TIF.